Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938282 | 0.96 | PORCN (0.55) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4133270 | 0.82 | CYP1A2 (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL30122990 | 0.82 | ALDH1A1 (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14937928 | 0.80 | PORCN (0.47) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3447723 | 0.80 | CYP1A2 (0.54) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL15950989 | 0.80 | COMT (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL30268376 | 0.79 | CYP2A6 (0.58) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13537099 | 0.79 | CYP2A6 (0.58) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14937987 | 0.79 | CYP2A6 (0.52) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL12742950 | 0.79 | KDM4E (0.43) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | claimed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| WO-2024107658-A2 | INHIBITORS OF TYK2 | VYRNWY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| EP-0872903-A1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | Shin-Etsu Chemical Co., Ltd. (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5468871-A | Catalytic N-alkylation | BASF AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0628563-A1 | Process for the preparation of N-substituted pyrazoles | BASF Aktiengesellschaft (DE) | 1994-12-14 | — | — | EP | disclosed |
| CN-1006386-B | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | SHINETSU CHEM IND CO (JP) | 1990-01-10 | — | — | CN | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | NPC1 1995/4885RAB9A 270/4885ALDH1A1 168/4885 |
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | NPC1 2436/4885RAB9A 519/4885ALDH1A1 300/4885 |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | NPC1 1041/4885RAB9A 3454/4885ALDH1A1 1680/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 859/4885RAB9A 876/4885ALDH1A1 4654/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | NPC1 2546/4885RAB9A 480/4885ALDH1A1 285/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | NPC1 4197/4885RAB9A 20/4885ALDH1A1 2972/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | NPC1 2546/4885RAB9A 480/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.